{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T20:29:08Z","timestamp":1649190548273},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00108-012-3152-0","type":"journal-article","created":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T08:30:32Z","timestamp":1359534632000},"page":"155-163","source":"Crossref","is-referenced-by-count":2,"title":["Ma\u00dfgeschneiderte Therapie der chronischen myeloischen Leuk\u00e4mie"],"prefix":"10.1007","volume":"54","author":[{"given":"A.","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"La Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,1]]},"reference":[{"key":"3152_CR1","doi-asserted-by":"crossref","unstructured":"Apperley JF, Cortes JE, Kim DW et\u00a0al (2009) Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START\u00a0A trial. J\u00a0Clin Oncol 27:3472\u20133479","DOI":"10.1200\/JCO.2007.14.3339"},{"key":"3152_CR2","doi-asserted-by":"crossref","unstructured":"Baccarani M, Cortes J, Pane F et\u00a0al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J\u00a0Clin Oncol 27:6041\u20136051","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"3152_CR3","doi-asserted-by":"crossref","unstructured":"Burchert A, M\u00fcller MC, Kostrewa P et\u00a0al (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J\u00a0Clin Oncol 28:1429\u20131435","DOI":"10.1200\/JCO.2009.25.5075"},{"key":"3152_CR4","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","volume":"22","author":"Cortes","year":"2008","unstructured":"Cortes J, Kim DW, Raffoux E et\u00a0al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22:2176\u20132183","journal-title":"Leukemia"},{"key":"3152_CR5","doi-asserted-by":"crossref","unstructured":"Cortes JE, Kim DW, Kantarjian HM et\u00a0al (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J\u00a0Clin Oncol 30:3486\u20133492","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"3152_CR6","first-page":"186","volume":"8","author":"Cross","year":"1994","unstructured":"Cross NC, Melo JV, Feng L et\u00a0al (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8:186\u2013189","journal-title":"Leukemia"},{"key":"3152_CR7","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"Cross","year":"2012","unstructured":"Cross NC, White HE, M\u00fcller MC et\u00a0al (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172\u20132175","journal-title":"Leukemia"},{"key":"3152_CR8","doi-asserted-by":"crossref","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et\u00a0al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N\u00a0Engl J Med 355:2408\u20132417","DOI":"10.1056\/NEJMoa062867"},{"key":"3152_CR9","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.12964","volume":"93","author":"Ernst","year":"2008","unstructured":"Ernst T, Hoffmann J, Erben P et\u00a0al (2008) ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 93:1389\u20131393","journal-title":"Haematologica"},{"key":"3152_CR10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2011.09.005","volume":"25","author":"Ernst","year":"2011","unstructured":"Ernst T, La Rosee P, Muller MC et\u00a0al (2011) BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am 25:997\u20131008","journal-title":"Hematol Oncol Clin North Am"},{"key":"3152_CR11","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A et\u00a0al (2011) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151\u00a0patients from the randomized CML Study IV. Blood 118:6760\u20136768","journal-title":"Blood"},{"key":"3152_CR12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","volume":"26","author":"Giles","year":"2012","unstructured":"Giles FJ, Kantarjian HM, Le Coutre PD et\u00a0al (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:959\u2013962","journal-title":"Leukemia"},{"key":"3152_CR13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM et\u00a0al (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352:1087\u20131092","journal-title":"Lancet"},{"key":"3152_CR14","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R et\u00a0al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096\u20132102","journal-title":"Leukemia"},{"key":"3152_CR15","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V et\u00a0al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060\u00a0patients with CML on imatinib treatment: the EUTOS score. Blood 118:686\u2013692","journal-title":"Blood"},{"key":"3152_CR16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"Hehlmann","year":"2012","unstructured":"Hehlmann R (2012) How I treat CML blast crisis. Blood 120:737\u2013747","journal-title":"Blood"},{"key":"3152_CR17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M (2007) Chronic myeloid leukaemia. Lancet 370:342\u2013350","journal-title":"Lancet"},{"key":"3152_CR18","doi-asserted-by":"crossref","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S et\u00a0al (2011) Tolerability-adapted imatinib 800\u00a0mg\/d versus 400\u00a0mg\/d versus 400\u00a0mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J\u00a0Clin Oncol 29:1634\u20131642","DOI":"10.1200\/JCO.2010.32.0598"},{"key":"3152_CR19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M et\u00a0al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200\u20131206","journal-title":"Leukemia"},{"key":"3152_CR20","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"Hochhaus","year":"2004","unstructured":"Hochhaus A, La Ros\u00e9e P (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18:1321\u20131331","journal-title":"Leukemia"},{"key":"3152_CR21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4161\/cc.10.2.14537","volume":"10","author":"Hochhaus","year":"2011","unstructured":"Hochhaus A, La Ros\u00e9e P, M\u00fcller MC et\u00a0al (2011) Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 10:250\u2013260","journal-title":"Cell Cycle"},{"key":"3152_CR22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F et\u00a0al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061","journal-title":"Leukemia"},{"key":"3152_CR23","doi-asserted-by":"crossref","unstructured":"Hughes T, Saglio G, Branford S et\u00a0al (2009) Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J\u00a0Clin Oncol 27:4204\u20134210","DOI":"10.1200\/JCO.2009.21.8230"},{"key":"3152_CR24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","volume":"25","author":"Jabbour","year":"2011","unstructured":"Jabbour E, Deininger M, Hochhaus A (2011) Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25:201\u2013210","journal-title":"Leukemia"},{"key":"3152_CR25","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Shah NP, Hochhaus A et\u00a0al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N\u00a0Engl J Med 362:2260\u20132270","DOI":"10.1056\/NEJMoa1002315"},{"key":"3152_CR26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN et\u00a0al (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117:1141\u20131145","journal-title":"Blood"},{"key":"3152_CR27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE et\u00a0al (2012) Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase\u00a03 trial (DASISION). Blood 119:1123\u20131129","journal-title":"Blood"},{"key":"3152_CR28","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP et\u00a0al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197\u20132203","journal-title":"Leukemia"},{"key":"3152_CR29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","volume":"26","author":"Le","year":"2012","unstructured":"Le Coutre PD, Giles FJ, Hochhaus A et\u00a0al (2012) Nilotinib in patients with Ph\u2009+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26:1189\u20131194","journal-title":"Leukemia"},{"key":"3152_CR30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J et\u00a0al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"3152_CR31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","volume":"95","author":"Milojkovic","year":"2010","unstructured":"Milojkovic D, Nicholson E, Apperley JF et\u00a0al (2010) Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95:224\u2013231","journal-title":"Haematologica"},{"key":"3152_CR32","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","volume":"114","author":"M\u00fcller","year":"2009","unstructured":"M\u00fcller MC, Cortes JE, Kim DW et\u00a0al (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944\u20134953","journal-title":"Blood"},{"key":"3152_CR33","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2011-07-367326","volume":"118","author":"Nicolini","year":"2011","unstructured":"Nicolini FE, Basak GW, Soverini S et\u00a0al (2011) Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 118:5697\u20135700","journal-title":"Blood"},{"key":"3152_CR34","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA et\u00a0al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N\u00a0Engl J Med 348:994\u20131004","DOI":"10.1056\/NEJMoa022457"},{"key":"3152_CR35","doi-asserted-by":"crossref","unstructured":"Preudhomme C, Guilhot J, Nicolini FE et\u00a0al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N\u00a0Engl J Med 363:2511\u20132521","DOI":"10.1056\/NEJMoa1004095"},{"key":"3152_CR36","doi-asserted-by":"crossref","unstructured":"Saglio G, Kim DW, Issaragrisil S et\u00a0al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N\u00a0Engl J Med 362:2251\u20132259","DOI":"10.1056\/NEJMoa0912614"},{"key":"3152_CR37","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A et\u00a0al (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study\u00a0IV. Blood 115:1880\u20131885","journal-title":"Blood"},{"key":"3152_CR38","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE et\u00a0al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118:1208\u20131215","journal-title":"Blood"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-012-3152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-012-3152-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-012-3152-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:17:33Z","timestamp":1558570653000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-012-3152-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["3152"],"URL":"https:\/\/doi.org\/10.1007\/s00108-012-3152-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}